Open AccessBrentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
Author(s) -
А. А. Семенова,
P. A. Zeynalovа,
Maritta Ņikitina,
Mobil Akhmedov
Publication year - 2019
Publication title -
onkogematologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.118
H-Index - 3
eISSN - 2413-4023
pISSN - 1818-8346
DOI - 10.17650/1818-8346-2019-13-4-54-59
Subject(s) - brentuximab vedotin , anaplastic large cell lymphoma , medicine , lymphoma , oncology , cd30 , refractory (planetary science) , monoclonal antibody , cancer research , antibody , immunology , biology , astrobiology
The introduction of new monoclonal antibodies has become an integral part of the treatment of malignant tumors. Brentuximab vedotin (Adcetris®) – anti-D30 monoclonal antibody conjugated with monomethyluristatin E – has become a new drug registered since February 2016 in the Russian Federation (SGN-35; Adcetris®). The Food and Drug Administration approved the Adcetris® since August 2011 as a therapy for refractory/recurrent Hodgkin’s lymphoma and anaplastic large cell lymphoma. This article describes the clinical case of successful use of Brentuximab vedotin, accompanied by the development of a rare complication – tumor lysis syndrome – in an elderly patient with primary refractory ALK-negative anaplastic large cell lymphoma with massive eosinophilia.